These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 34135101)

  • 1. Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images.
    Mu W; Jiang L; Shi Y; Tunali I; Gray JE; Katsoulakis E; Tian J; Gillies RJ; Schabath MB
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34135101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Value of
    Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
    Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images.
    Tian P; He B; Mu W; Liu K; Liu L; Zeng H; Liu Y; Jiang L; Zhou P; Huang Z; Dong D; Li W
    Theranostics; 2021; 11(5):2098-2107. PubMed ID: 33500713
    [No Abstract]   [Full Text] [Related]  

  • 5. [Construction of A Nomogram Prediction Model for PD-L1 Expression 
in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters].
    Hao L; Wang L; Zhang M; Yan J; Zhang F
    Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):833-842. PubMed ID: 38061885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
    Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
    J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CT-based deep learning radiomics biomarker for programmed cell death ligand 1 expression in non-small cell lung cancer.
    Xu T; Liu X; Chen Y; Wang S; Jiang C; Gong J
    BMC Med Imaging; 2024 Jul; 24(1):196. PubMed ID: 39085788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting PD-L1 expression status in patients with non-small cell lung cancer using [
    Zhao X; Zhao Y; Zhang J; Zhang Z; Liu L; Zhao X
    EJNMMI Res; 2023 Jan; 13(1):4. PubMed ID: 36682020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.
    Rakaee M; Adib E; Ricciuti B; Sholl LM; Shi W; Alessi JV; Cortellini A; Fulgenzi CAM; Viola P; Pinato DJ; Hashemi S; Bahce I; Houda I; Ulas EB; Radonic T; Väyrynen JP; Richardsen E; Jamaly S; Andersen S; Donnem T; Awad MM; Kwiatkowski DJ
    JAMA Oncol; 2023 Jan; 9(1):51-60. PubMed ID: 36394839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Automated PD-L1 status prediction in lung cancer with multi-modal PET/CT fusion.
    Da-Ano R; Andrade-Miranda G; Tankyevych O; Visvikis D; Conze PH; Rest CCL
    Sci Rep; 2024 Jul; 14(1):16720. PubMed ID: 39030240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
    Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
    Front Immunol; 2021; 12():646874. PubMed ID: 33927719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB-IV NSCLC (LCDigital-IO Study): a multicenter retrospective study.
    Wu S; Zhan W; Liu L; Xie D; Yao L; Yao H; Liao G; Huang L; Zhou Y; You P; Huang Z; Li Q; Xu B; Wang S; Wang G; Zhang DK; Qiao G; Chan LW; Lanuti M; Zhou H
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37865396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiomics predicts risk of cachexia in advanced NSCLC patients treated with immune checkpoint inhibitors.
    Mu W; Katsoulakis E; Whelan CJ; Gage KL; Schabath MB; Gillies RJ
    Br J Cancer; 2021 Jul; 125(2):229-239. PubMed ID: 33828255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A deep-learning model using enhanced chest CT images to predict PD-L1 expression in non-small-cell lung cancer patients.
    Liu PM; Feng B; Shi JF; Feng HJ; Hu ZJ; Chen YH; Zhang JP
    Clin Radiol; 2023 Oct; 78(10):e689-e697. PubMed ID: 37460338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The "digital biopsy" in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT.
    Monaco L; De Bernardi E; Bono F; Cortinovis D; Crivellaro C; Elisei F; L'Imperio V; Landoni C; Mathoux G; Musarra M; Pagni F; Turolla EA; Messa C; Guerra L
    Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3401-3411. PubMed ID: 35403860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC.
    Wang C; Ma J; Shao J; Zhang S; Li J; Yan J; Zhao Z; Bai C; Yu Y; Li W
    Front Immunol; 2022; 13():828560. PubMed ID: 35464416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiomics of
    Mu W; Tunali I; Gray JE; Qi J; Schabath MB; Gillies RJ
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1168-1182. PubMed ID: 31807885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.